Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos M, Lanillos J, Caleiras E, Valdivia C, Roldan-Romero JM, Laínez N, Puente J, Beuselinck B, Oudard S, Zucman-Rossi J, Navarro P, Robledo M, Castellano D, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Among authors: beuselinck b. Am J Cancer Res. 2023 May 15;13(5):2116-2125. eCollection 2023. Am J Cancer Res. 2023. PMID: 37293154 Free PMC article.
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi AL, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Gonçalves LCP, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M. Montemagno C, et al. Among authors: beuselinck b. J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2. J Exp Clin Cancer Res. 2024. PMID: 38504270 Free PMC article.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Weber J, et al. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891423 Free article. Clinical Trial.
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar SA, Weise N, Hall WA, Rose BS, Beuselinck B, Suarez C, Pal SK, Choueiri TK, Heng DYC, McKay RR. Loo Gan C, et al. Among authors: beuselinck b. Eur Urol Oncol. 2023 Apr;6(2):204-211. doi: 10.1016/j.euo.2022.10.004. Epub 2022 Nov 1. Eur Urol Oncol. 2023. PMID: 36328934
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study.
Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, Singla N, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. Duarte C, et al. Among authors: beuselinck b. EClinicalMedicine. 2023 Jun 1;60:102018. doi: 10.1016/j.eclinm.2023.102018. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37304495 Free PMC article.
Predicting short- and long-term renal function following partial and radical nephrectomy.
Roussel E, Laenen A, Bhindi B, De Dobbeleer A, Stichele AV, Verbeke L, Van Cleynenbreugel B, Sprangers B, Beuselinck B, Van Poppel H, Joniau S, Albersen M. Roussel E, et al. Among authors: beuselinck b. Urol Oncol. 2023 Feb;41(2):110.e1-110.e6. doi: 10.1016/j.urolonc.2022.10.006. Epub 2022 Nov 10. Urol Oncol. 2023. PMID: 36372636
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Yuasa T, Lemelin A, Ferrier E, Wells JC, Saad E, Saliby RM, Basappa NS, Wood LA, Jude E, Pal SK, Donskov F, Beuselinck B, Szabados B, Powles T, McKay RR, Gebrael G, Agarwal N, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: beuselinck b. ESMO Open. 2024 Jul;9(7):103606. doi: 10.1016/j.esmoop.2024.103606. Epub 2024 Jun 19. ESMO Open. 2024. PMID: 38901174 Free PMC article.
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, Dubroja N, Shankar G, Bosisio FM, Roussel E, Verbiest A, Finotello F, Ausserhofer M, Lambrechts D, Boeckx B, Wozniak A, Boon L, Kerkhofs J, Zucman-Rossi J, Albersen M, Baldewijns M, Beuselinck B, Garg AD. Kinget L, et al. Among authors: beuselinck b. Nat Med. 2024 Jun;30(6):1667-1679. doi: 10.1038/s41591-024-02978-9. Epub 2024 May 21. Nat Med. 2024. PMID: 38773341
136 results